JP6077710B2 - がん療法のためのリポソームシスプラチン組成物 - Google Patents

がん療法のためのリポソームシスプラチン組成物 Download PDF

Info

Publication number
JP6077710B2
JP6077710B2 JP2016502107A JP2016502107A JP6077710B2 JP 6077710 B2 JP6077710 B2 JP 6077710B2 JP 2016502107 A JP2016502107 A JP 2016502107A JP 2016502107 A JP2016502107 A JP 2016502107A JP 6077710 B2 JP6077710 B2 JP 6077710B2
Authority
JP
Japan
Prior art keywords
mol
composition
lipid
cisplatin
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513651A5 (enExample
JP2016513651A (ja
Inventor
ウィリアム マッギー，
ウィリアム マッギー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2016513651A publication Critical patent/JP2016513651A/ja
Publication of JP2016513651A5 publication Critical patent/JP2016513651A5/ja
Application granted granted Critical
Publication of JP6077710B2 publication Critical patent/JP6077710B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2016502107A 2013-03-13 2014-03-13 がん療法のためのリポソームシスプラチン組成物 Expired - Fee Related JP6077710B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
US61/780,272 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (3)

Publication Number Publication Date
JP2016513651A JP2016513651A (ja) 2016-05-16
JP2016513651A5 JP2016513651A5 (enExample) 2016-12-22
JP6077710B2 true JP6077710B2 (ja) 2017-02-08

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502107A Expired - Fee Related JP6077710B2 (ja) 2013-03-13 2014-03-13 がん療法のためのリポソームシスプラチン組成物

Country Status (8)

Country Link
US (2) US10039716B2 (enExample)
EP (1) EP2968142A1 (enExample)
JP (1) JP6077710B2 (enExample)
CN (1) CN105209017A (enExample)
BR (1) BR112015022415A2 (enExample)
CA (1) CA2903254C (enExample)
MX (1) MX2015012199A (enExample)
WO (1) WO2014160337A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150063533A (ko) * 2012-10-01 2015-06-09 헤이신 엘티디. 토출 시스템

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CA2977397A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
PH12022550592A1 (en) * 2016-01-07 2023-07-17 Tesorx Pharma Llc Formulations for treating bladder cancer
WO2017142876A1 (en) 2016-02-15 2017-08-24 University Of Georgia Research Foundation, Inc. lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF
KR102483033B1 (ko) * 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
CA3050686A1 (en) * 2017-01-18 2018-07-26 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
EP3706801B1 (en) * 2017-11-08 2026-01-14 L.E.A.F Holdings Group LLC Platinum complexes and uses thereof
WO2021183588A1 (en) 2020-03-10 2021-09-16 Chung Yuan Christian University Liposome composition and preparation method thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
EA002630B1 (ru) 1997-02-05 2002-08-29 Фармация Энд Апджон Компани Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины
DE60110057T2 (de) * 2000-01-28 2005-09-08 Alza Corp., Mountain View Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
DE60222580T2 (de) * 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
JP5364381B2 (ja) 2006-12-08 2013-12-11 片山化学工業株式会社 アンミン白金錯体を高濃度で内包するリポソームおよびその製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150063533A (ko) * 2012-10-01 2015-06-09 헤이신 엘티디. 토출 시스템
KR102079414B1 (ko) 2012-10-01 2020-02-19 헤이신 엘티디. 토출 시스템

Also Published As

Publication number Publication date
MX2015012199A (es) 2015-11-30
CA2903254A1 (en) 2014-10-02
US20180318219A1 (en) 2018-11-08
CN105209017A (zh) 2015-12-30
BR112015022415A2 (pt) 2017-07-18
WO2014160337A1 (en) 2014-10-02
US10383823B2 (en) 2019-08-20
US10039716B2 (en) 2018-08-07
US20140271821A1 (en) 2014-09-18
EP2968142A1 (en) 2016-01-20
JP2016513651A (ja) 2016-05-16
CA2903254C (en) 2019-04-09

Similar Documents

Publication Publication Date Title
US10383823B2 (en) Liposomal cisplatin compositions for cancer therapy
JP6341987B2 (ja) がん治療のためのリポソームオキサリプラチン組成物
US10213385B2 (en) Combinational liposome compositions for cancer therapy
US20140271822A1 (en) Modified docetaxel liposome formulations
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
US20190328665A1 (en) Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
EP3811931B1 (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
EP3861987A1 (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
CN115605196A (zh) 用于治疗癌症和癌症耐药性的脂质体制剂
CN103479578A (zh) 一种马来酸匹杉琼的脂质体制剂及其制备工艺
Cosco et al. Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy
CN107708670A (zh) 磷脂包衣的治疗剂纳米颗粒和有关的方法
WO2017115301A1 (en) Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent
WO2023122577A2 (en) Methods of treating cancer using liposomal particles comprising anticancer agents and pharmaceutical compositions related thereto
WO2018106980A1 (en) Liposomal elinafide formulations and uses thereof
Maher Harnessing nanomedicine to potentiate the chemo-immuno-2 therapeutic effects of doxorubicin and alendronate co-encapsu-3 lated in pegylated liposomes
WO2018089481A1 (en) Mitomycin c prodrug liposome formulations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160803

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170112

R150 Certificate of patent or registration of utility model

Ref document number: 6077710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees